Extended trial tests promising drug to control rare liver disease

NCT ID NCT05899673

Summary

This study aims to learn about the long-term safety of a drug called fazirsiran for people with liver disease caused by Alpha-1 antitrypsin deficiency. It allows 31 participants from previous fazirsiran studies to continue receiving the drug every three months. The main goal is to monitor for side effects over time, while also checking if the treatment helps reduce or slow down liver scarring.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Addenbrooke's Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Hospital Nélio Mendonça

    Funchal, 9000-168, Portugal

  • Medical University of South Carolina - Hollings Cancer Center - PPDS

    Charleston, South Carolina, 29425-8900, United States

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, A-1090, Austria

  • Royal Infirmary of Edinburgh - PPDS

    Edinburgh, EH16 4SA, United Kingdom

  • Stanford Medicine Outpatient Center

    Redwood City, California, 94063, United States

  • UCSD Altman Clinical and Translational Research Institute

    La Jolla, California, 92037-1337, United States

  • UF Clinical and Translational Science Institute

    Gainesville, Florida, 32610-3010, United States

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa, 52242-1009, United States

  • Universitätsklinikum der RWTH Aachen

    Aachen, North Rhine-Westphalia, 52074, Germany

Conditions

Explore the condition pages connected to this study.